CTIC Insider Trading Activity and SEC Form 4 Filings
CTIC insider trading summary
No open-market insider purchases or sales of Cti Biopharma Corp (CTIC) have been reported on SEC Form 4 in the past 12 months.
Latest CTIC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 24, 2023 | Adam R Craig | President and CEO | Sell | $499K (83,200 @ $6.00) |
| Jan 24, 2023 | James K Fong | EVP & Chief Commercial Officer | Sell | $600K (100,000 @ $6.00) |
| Jan 24, 2023 | Adam R Craig | President and CEO | Sell | $13K (2,117 @ $6.01) |
| Jan 3, 2023 | David Kirske | EVP, Chief Financial Officer | Sell | $162K (27,021 @ $6.01) |
| Jan 3, 2023 | Adam R Craig | President and CEO | Sell | $509K (84,683 @ $6.01) |
| Dec 30, 2022 | Adam R Craig | President and CEO | Sell | $72K (12,000 @ $6.00) |
| Dec 30, 2022 | David Kirske | EVP, Chief Financial Officer | Sell | $5K (800 @ $6.00) |
| Dec 30, 2022 | Adam R Craig | President and CEO | Sell | $4K (700 @ $6.00) |
| Dec 30, 2022 | David Kirske | EVP, Chief Financial Officer | Sell | $72K (12,000 @ $6.00) |
| Dec 30, 2022 | David Kirske | EVP, Chief Financial Officer | Sell | $6K (1,047 @ $6.01) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.